What Is LMNA Cardiomyopathy and How Is It Treated?

LMNA cardiomyopathy is an inherited weakness of the heart muscle caused by a change in a single gene, LMNA.¹ It stands out among inherited heart muscle diseases because the heart’s electrical wiring often fails years before the muscle itself weakens.² That makes a sudden dangerous rhythm the main threat, so treatment focuses as much on protecting against rhythm problems as on supporting the heart’s pumping.

What the LMNA Gene Does in the Heart

The LMNA gene makes two closely related proteins, lamin A and lamin C, from the same set of instructions.³ Both line the inside of the nucleus, the compartment that holds a cell’s DNA, forming a supporting mesh. That mesh helps the nucleus keep its shape and sense physical forces.⁴

When the lamins are faulty, the nucleus becomes fragile. Cells lacking lamin A/C have nuclei that deform more under stretch and are more likely to die when strained.⁵ Heart cells grown from people with LMNA variants have misshapen or enlarged nuclei, and the worse the lamin assembly, the worse the damage.⁶

Lamins are found in almost every cell, but heart and skeletal muscle live under the most mechanical stress. That is why the same gene can cause muscle weakness in some families. It may also help explain why the heart’s electrical wiring is affected early.

One changed copy of the gene, from either parent, is enough to cause the disease. This is usually called dominant inheritance, and it means each child of a carrier has a 1 in 2 chance of inheriting the change. Some cases, especially severe ones in childhood, arise new in the child rather than coming from a parent. The cause has nothing to do with lifestyle, diet, or blocked arteries; it is built into the cells’ structure.

How LMNA Cardiomyopathy Shows Up and Progresses

Symptoms often begin in the third to fourth decade of life.⁷ Nearly 90% of carriers eventually develop the disease as they age.⁸ So carrying the variant without symptoms usually means it hasn’t shown up yet, not that it never will.

Electrical problems typically come first. Signals between the heart’s upper and lower chambers may be blocked, or the rhythm may turn irregular, often before the muscle weakens.⁹ On average, changes on an ECG appear about seven years before the heart enlarges and weakens.¹⁰

What you notice depends on the stage. Fainting or near-fainting can mean a very slow or very fast rhythm. Palpitations, a fluttering or racing heart, can signal atrial fibrillation. Tiredness and breathlessness on stairs often come later, as pumping weakens, and swollen ankles or needing pillows to sleep flat suggest heart failure.

Some carriers also have muscle weakness and stiff joints, a pattern doctors may call Emery-Dreifuss muscular dystrophy. Milder forms cause weakness in the hips and shoulders that starts in adulthood. Children whose muscle involvement starts before age 2 can develop heart weakness quickly.

A known carrier who faints needs prompt medical review rather than waiting for the next checkup. Report new palpitations to your heart team. Chest pain or a collapse calls for emergency services.

Why Sudden Death Risk Is Higher Than With Other Causes

Among people with an enlarged, weak heart, those with LMNA variants had about four times the rate of serious events as those with no gene found.¹¹ They also more often reached end-stage heart failure than most other gene groups.¹²

Sudden death was the most common way carriers died, in 46% of reported deaths.¹³ The risk was similar whether a person’s disease mostly affected the heart or the muscles.¹⁴ Dangerous fast rhythms often occur before severe pumping loss,¹⁵ so a reassuring pumping-strength number alone doesn’t mean low risk for LMNA carriers. That number is the ejection fraction: the share of blood the main pumping chamber pushes out with each beat, normally about 55 to 70%. In many heart conditions, defibrillators are considered mainly when it falls to 35% or lower. LMNA is an exception, because rhythms turn dangerous earlier and doctors act sooner.

Sudden death is largely preventable with a defibrillator, which is why risk assessment matters so much.

Defibrillators and How Doctors Decide Who Needs One

Doctors can estimate a carrier’s 5-year risk of a life-threatening fast rhythm with the LMNA-risk VTA calculator at lmna-risk-vta.fr.¹⁶ It combines sex, type of gene change, blocked heart signals, short runs of fast rhythm, and pumping strength.¹⁷ A 5-year risk of 7% or higher caught about 96% of the people who went on to have such rhythms.¹⁸

The calculator has limits. In another group of patients, it flagged most who later had dangerous rhythms, but many it flagged never did.¹⁹ It tended to overestimate risk in people with mild or moderate disease, especially men.²⁰ Rechecking risk at each visit caught every person before their event,²¹ so ask for your risk to be recalculated at each yearly visit, not just once.

An ICD (implantable cardioverter-defibrillator) is a small device placed under the skin near the collarbone, with a wire running into the heart. It watches every beat and delivers a shock to stop a dangerous fast rhythm. It can also act as a pacemaker if the heart beats too slowly. A shock feels like a sudden hard kick in the chest, and you should report it to your team. Living with a device means regular checks, often done remotely from home.

Many carriers first need pacing for slow rhythms caused by blocked signals. Because the rhythm risk is high, doctors often choose a device that can also shock. Ask whether a combined device suits you before any pacemaker is fitted.

Tests Used to Monitor the Heart

People at risk should be checked at least once a year, especially once any ECG change appears.²² All carriers need screening for fast rhythms in particular.²³

An ECG takes minutes, with stickers on the chest. A wearable monitor worn for 24 to 48 hours catches rhythms that come and go. An echocardiogram uses ultrasound to measure pumping. An MRI takes about an hour inside a scanner, with dye injected.

Cardiac MRI with contrast can show scar in the heart wall, which your report may list as late gadolinium enhancement (LGE).²⁴ In one group, dangerous rhythms happened only in people with scarring, 8 of 25, versus none of 16 without.²⁵ The scarring typically sits in the wall between the two pumping chambers,²⁶ and the more scarring, the higher the chance of serious heart events.²⁷

Medicines, Pacing, and Other Treatments

When pumping weakens, doctors usually prescribe the standard four groups of heart failure medicines. These include sacubitril/valsartan, beta-blockers, spironolactone-type drugs, and SGLT2 inhibitors.²⁸ No medicine yet targets the faulty lamin itself.²⁹

Atrial fibrillation, an irregular rhythm in the upper chambers, is common in carriers. It raises stroke risk, so blood thinners are often prescribed, with rate or rhythm medicines used alongside.

A pacing device with an extra wire, called CRT, can make both sides of the heart beat together. People who already rely heavily on a pacemaker are among those most likely to benefit.³⁰ Fitting it early, when a device is already needed, may slow worsening heart failure.³¹

Burning away rhythm sources with a catheter, called ablation, works poorly in LMNA disease. The problem tissue lies deep in the wall between the pumping chambers,³² and 91% had the rhythm return within months.³³ A defibrillator therefore stays the main protection, with ablation kept for repeated shocks.

About 1 in 5 patients needed a heart transplant over roughly 8 years of follow-up.³⁴ Pumps that support the heart can bridge people to transplant.³⁵

Useful questions for your clinic: Are you on all the medicine groups at the right dose? Would CRT make sense with your current device? When should you be referred to an advanced heart failure center?

Family Testing

Once a variant is found, parents, siblings, and children can be tested for that same change. Relatives who carry it should be considered for cardiac MRI at their first check.³⁶

A genetic counselor explains the results first. Testing is usually a blood or saliva sample. Relatives who test negative generally need no ongoing checks, and the timing of testing for children is discussed with the family.

Exercise and Daily Life

Carriers who exercised more over their lives had weaker pumping, with ejection fraction about 4 points lower for each step up in lifetime exercise.³⁷ In mice with an LMNA change, hard running brought heart weakening on earlier.³⁸ Discuss intensity limits with your cardiologist.

Walking and light cycling are usually encouraged. Competitive and endurance sports are often discouraged, and a defibrillator can limit contact sports. Plans are tailored to your test results.

Limit alcohol, which can trigger irregular rhythm. Report pregnancy plans early so you can get specialist care. Keep a current medicine and device list on your phone.

Treatments Being Tested

A pill blocking a stress signal in heart cells, ARRY-371797, prevented heart enlargement in mice with LMNA disease.³⁹ In 12 patients it improved how far they could walk in six minutes over 48 weeks.⁴⁰ It became the first drug tested specifically for LMNA cardiomyopathy.⁴¹

Gene editing has also shown promise. Editing the faulty letter of DNA prevented heart enlargement in mice,⁴² and it nearly doubled survival in severely affected mice.⁴³ This has only been done in animals so far.

To look into trials, ask your clinic or patient groups about registries, and check listings on clinicaltrials.gov. Results in small groups don’t guarantee approval.